CA3239023A1 - Utilisation d'un ou de plusieurs biomarqueurs pour determiner un traumatisme cranien (tbi) chez un sujet ayant ete soumis a un balayage de tomodensitometrie assistee par ordinateur de la tete ne demontrant par de tb - Google Patents
Utilisation d'un ou de plusieurs biomarqueurs pour determiner un traumatisme cranien (tbi) chez un sujet ayant ete soumis a un balayage de tomodensitometrie assistee par ordinateur de la tete ne demontrant par de tb Download PDFInfo
- Publication number
- CA3239023A1 CA3239023A1 CA3239023A CA3239023A CA3239023A1 CA 3239023 A1 CA3239023 A1 CA 3239023A1 CA 3239023 A CA3239023 A CA 3239023A CA 3239023 A CA3239023 A CA 3239023A CA 3239023 A1 CA3239023 A1 CA 3239023A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- subject
- sample
- tbi
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000030886 Traumatic Brain injury Diseases 0.000 title claims abstract description 240
- 230000009529 traumatic brain injury Effects 0.000 title claims abstract description 238
- 239000000090 biomarker Substances 0.000 title claims abstract description 53
- 238000003325 tomography Methods 0.000 title claims description 13
- 238000000034 method Methods 0.000 claims abstract description 304
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 claims abstract description 240
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims abstract description 240
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims abstract description 239
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 claims abstract description 110
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 claims abstract description 110
- 238000002591 computed tomography Methods 0.000 claims abstract description 53
- 238000003556 assay Methods 0.000 claims description 237
- 208000014674 injury Diseases 0.000 claims description 142
- 230000006378 damage Effects 0.000 claims description 133
- 208000027418 Wounds and injury Diseases 0.000 claims description 131
- 238000003018 immunoassay Methods 0.000 claims description 66
- 210000004369 blood Anatomy 0.000 claims description 50
- 239000008280 blood Substances 0.000 claims description 50
- 230000002459 sustained effect Effects 0.000 claims description 48
- 210000002966 serum Anatomy 0.000 claims description 41
- 239000000126 substance Substances 0.000 claims description 39
- 230000006872 improvement Effects 0.000 claims description 30
- 210000001519 tissue Anatomy 0.000 claims description 28
- 210000002381 plasma Anatomy 0.000 claims description 26
- 239000003053 toxin Substances 0.000 claims description 24
- 231100000765 toxin Toxicity 0.000 claims description 24
- 210000003296 saliva Anatomy 0.000 claims description 23
- 206010019196 Head injury Diseases 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- 238000004557 single molecule detection Methods 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 19
- 238000012544 monitoring process Methods 0.000 claims description 15
- 208000000044 Amnesia Diseases 0.000 claims description 11
- 201000009906 Meningitis Diseases 0.000 claims description 11
- 238000003745 diagnosis Methods 0.000 claims description 11
- 238000011156 evaluation Methods 0.000 claims description 11
- 230000008733 trauma Effects 0.000 claims description 11
- 230000002596 correlated effect Effects 0.000 claims description 10
- 208000031091 Amnestic disease Diseases 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 208000035143 Bacterial infection Diseases 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 9
- 206010017533 Fungal infection Diseases 0.000 claims description 9
- 206010021143 Hypoxia Diseases 0.000 claims description 9
- 208000031888 Mycoses Diseases 0.000 claims description 9
- 208000003443 Unconsciousness Diseases 0.000 claims description 9
- 208000036142 Viral infection Diseases 0.000 claims description 9
- 230000006986 amnesia Effects 0.000 claims description 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 9
- 230000007954 hypoxia Effects 0.000 claims description 9
- 208000030159 metabolic disease Diseases 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- 230000009385 viral infection Effects 0.000 claims description 9
- 210000001124 body fluid Anatomy 0.000 claims description 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 8
- 239000003292 glue Substances 0.000 claims description 8
- 208000003906 hydrocephalus Diseases 0.000 claims description 8
- 239000003973 paint Substances 0.000 claims description 8
- 239000010425 asbestos Substances 0.000 claims description 7
- 238000004880 explosion Methods 0.000 claims description 7
- 239000002917 insecticide Substances 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 239000000575 pesticide Substances 0.000 claims description 7
- 229910052895 riebeckite Inorganic materials 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 claims description 7
- 239000000523 sample Substances 0.000 description 375
- 239000000427 antigen Substances 0.000 description 174
- 108091007433 antigens Proteins 0.000 description 168
- 102000036639 antigens Human genes 0.000 description 168
- 210000004027 cell Anatomy 0.000 description 148
- 210000003128 head Anatomy 0.000 description 136
- 239000012491 analyte Substances 0.000 description 122
- 230000027455 binding Effects 0.000 description 118
- 238000009739 binding Methods 0.000 description 117
- 230000009870 specific binding Effects 0.000 description 103
- 239000012634 fragment Substances 0.000 description 99
- 235000001014 amino acid Nutrition 0.000 description 96
- 229940024606 amino acid Drugs 0.000 description 94
- 150000001413 amino acids Chemical class 0.000 description 94
- 238000012360 testing method Methods 0.000 description 87
- 108090000623 proteins and genes Proteins 0.000 description 74
- 238000001514 detection method Methods 0.000 description 67
- 108060003951 Immunoglobulin Proteins 0.000 description 63
- 102000018358 immunoglobulin Human genes 0.000 description 63
- 108090000765 processed proteins & peptides Proteins 0.000 description 60
- 210000004408 hybridoma Anatomy 0.000 description 55
- 241001465754 Metazoa Species 0.000 description 43
- 102000004169 proteins and genes Human genes 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 41
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 40
- 239000007787 solid Substances 0.000 description 40
- 102000004196 processed proteins & peptides Human genes 0.000 description 39
- 239000003795 chemical substances by application Substances 0.000 description 36
- 229920001184 polypeptide Polymers 0.000 description 35
- 125000003275 alpha amino acid group Chemical group 0.000 description 34
- 238000011282 treatment Methods 0.000 description 34
- -1 MnAs Inorganic materials 0.000 description 33
- 238000005516 engineering process Methods 0.000 description 31
- 201000010099 disease Diseases 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 102000014914 Carrier Proteins Human genes 0.000 description 28
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 28
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 28
- 108091008324 binding proteins Proteins 0.000 description 28
- 239000013604 expression vector Substances 0.000 description 27
- 238000003259 recombinant expression Methods 0.000 description 25
- 239000001963 growth medium Substances 0.000 description 24
- 230000035945 sensitivity Effects 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 239000011324 bead Substances 0.000 description 23
- 230000005291 magnetic effect Effects 0.000 description 23
- 239000003153 chemical reaction reagent Substances 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 238000012216 screening Methods 0.000 description 22
- 230000009261 transgenic effect Effects 0.000 description 22
- 239000012530 fluid Substances 0.000 description 21
- 108700012359 toxins Proteins 0.000 description 21
- 206010035226 Plasma cell myeloma Diseases 0.000 description 20
- 208000029028 brain injury Diseases 0.000 description 19
- 241000196324 Embryophyta Species 0.000 description 18
- 201000000050 myeloid neoplasm Diseases 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 17
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 230000004927 fusion Effects 0.000 description 15
- 238000002595 magnetic resonance imaging Methods 0.000 description 15
- 230000003053 immunization Effects 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 13
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 238000001890 transfection Methods 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 206010010071 Coma Diseases 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 239000011859 microparticle Substances 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 238000002823 phage display Methods 0.000 description 12
- 102000040430 polynucleotide Human genes 0.000 description 12
- 108091033319 polynucleotide Proteins 0.000 description 12
- 239000002157 polynucleotide Substances 0.000 description 12
- 239000007790 solid phase Substances 0.000 description 12
- 101000888419 Homo sapiens Glial fibrillary acidic protein Proteins 0.000 description 11
- 102000051520 human GFAP Human genes 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 230000016784 immunoglobulin production Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 201000009032 substance abuse Diseases 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 9
- 108091035707 Consensus sequence Proteins 0.000 description 9
- 230000009824 affinity maturation Effects 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 239000003637 basic solution Substances 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000004602 germ cell Anatomy 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 229940072221 immunoglobulins Drugs 0.000 description 9
- 241001678559 COVID-19 virus Species 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 101000759926 Homo sapiens Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 8
- 241001494479 Pecora Species 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 239000001506 calcium phosphate Substances 0.000 description 8
- 229960001714 calcium phosphate Drugs 0.000 description 8
- 229910000389 calcium phosphate Inorganic materials 0.000 description 8
- 235000011010 calcium phosphates Nutrition 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 210000003527 eukaryotic cell Anatomy 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 102000057986 human UCHL1 Human genes 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 229960000485 methotrexate Drugs 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000002731 protein assay Methods 0.000 description 8
- 238000002818 protein evolution Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000011830 transgenic mouse model Methods 0.000 description 8
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 8
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 7
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 7
- 238000002820 assay format Methods 0.000 description 7
- 230000001588 bifunctional effect Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000009977 dual effect Effects 0.000 description 7
- 239000007850 fluorescent dye Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 210000003625 skull Anatomy 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000004611 spectroscopical analysis Methods 0.000 description 7
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- 208000007333 Brain Concussion Diseases 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- 244000061176 Nicotiana tabacum Species 0.000 description 6
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 6
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 6
- 108010039491 Ricin Proteins 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000004590 computer program Methods 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000002452 interceptive effect Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 150000007523 nucleic acids Chemical group 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 210000004989 spleen cell Anatomy 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- MRMOZBOQVYRSEM-UHFFFAOYSA-N tetraethyllead Chemical compound CC[Pb](CC)(CC)CC MRMOZBOQVYRSEM-UHFFFAOYSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102100029727 Enteropeptidase Human genes 0.000 description 5
- 108010013369 Enteropeptidase Proteins 0.000 description 5
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 5
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 108090000526 Papain Proteins 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 5
- 108090000284 Pepsin A Proteins 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 108090000848 Ubiquitin Proteins 0.000 description 5
- 102000044159 Ubiquitin Human genes 0.000 description 5
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 5
- 210000001130 astrocyte Anatomy 0.000 description 5
- 230000008827 biological function Effects 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 238000012875 competitive assay Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000699802 Cricetulus griseus Species 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- 108091029865 Exogenous DNA Proteins 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- QBFNAVMTMIICEI-UHFFFAOYSA-N acridine-9-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=C(C=CC=C3)C3=NC2=C1 QBFNAVMTMIICEI-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 210000000628 antibody-producing cell Anatomy 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010382 chemical cross-linking Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000009514 concussion Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
- 108020001096 dihydrofolate reductase Proteins 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 239000000833 heterodimer Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000000760 immunoelectrophoresis Methods 0.000 description 4
- 230000008676 import Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000007917 intracranial administration Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000006249 magnetic particle Substances 0.000 description 4
- 235000009973 maize Nutrition 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 238000001823 molecular biology technique Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 238000000730 protein immunoprecipitation Methods 0.000 description 4
- 238000001711 protein immunostaining Methods 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 230000006337 proteolytic cleavage Effects 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 238000012340 reverse transcriptase PCR Methods 0.000 description 4
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 3
- 206010002653 Anosmia Diseases 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- 108020004635 Complementary DNA Chemical group 0.000 description 3
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 3
- 101150074155 DHFR gene Proteins 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108090001090 Lectins Chemical group 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- JJWSNOOGIUMOEE-UHFFFAOYSA-N Monomethylmercury Chemical compound [Hg]C JJWSNOOGIUMOEE-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000272144 Naja atra Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 238000012452 Xenomouse strains Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 201000007201 aphasia Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000006957 competitive inhibition Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 239000002523 lectin Chemical group 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 108020001580 protein domains Proteins 0.000 description 3
- 238000002708 random mutagenesis Methods 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- FXZCCINCKDATPA-UHFFFAOYSA-N (4-aminophenyl) dihydrogen phosphate Chemical compound NC1=CC=C(OP(O)(O)=O)C=C1 FXZCCINCKDATPA-UHFFFAOYSA-N 0.000 description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- 108010066676 Abrin Proteins 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- 244000303258 Annona diversifolia Species 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 241000228254 Aspergillus restrictus Species 0.000 description 2
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000018652 Closed Head injury Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 2
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 208000003164 Diplopia Diseases 0.000 description 2
- 229910052692 Dysprosium Inorganic materials 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 101150057182 GFAP gene Proteins 0.000 description 2
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 244000207740 Lemna minor Species 0.000 description 2
- 235000006439 Lemna minor Nutrition 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 229910016629 MnBi Inorganic materials 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 101710204212 Neocarzinostatin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 231100000742 Plant toxin Toxicity 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 235000001855 Portulaca oleracea Nutrition 0.000 description 2
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 108010084592 Saporins Proteins 0.000 description 2
- 102000005686 Serum Globulins Human genes 0.000 description 2
- 108010045362 Serum Globulins Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 239000002776 alpha toxin Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000011504 assay standardization Methods 0.000 description 2
- 230000003140 astrocytic effect Effects 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 238000012832 cell culture technique Methods 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 239000012504 chromatography matrix Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 238000003094 enzyme-multiplied immunoassay technique Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000005293 ferrimagnetic effect Effects 0.000 description 2
- 239000002902 ferrimagnetic material Substances 0.000 description 2
- 230000005294 ferromagnetic effect Effects 0.000 description 2
- 239000003302 ferromagnetic material Substances 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000003500 gene array Methods 0.000 description 2
- 229960003569 hematoporphyrin Drugs 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 102000054751 human RUNX1T1 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000003963 intermediate filament Anatomy 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000008449 language Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004880 lymph fluid Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- 238000002610 neuroimaging Methods 0.000 description 2
- 230000001254 nonsecretory effect Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 125000001151 peptidyl group Chemical group 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229940080469 phosphocellulose Drugs 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 239000003123 plant toxin Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 150000003834 purine nucleoside derivatives Chemical class 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000002702 ribosome display Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002955 secretory cell Anatomy 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 229940056501 technetium 99m Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000006163 transport media Substances 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 229950009268 zinostatin Drugs 0.000 description 2
- CKRJGDYKYQUNIM-UHFFFAOYSA-N 3-fluoro-2,2-dimethylpropanoic acid Chemical compound FCC(C)(C)C(O)=O CKRJGDYKYQUNIM-UHFFFAOYSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000013883 Blast injury Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000007774 Broca Aphasia Diseases 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 206010010301 Confusion and disorientation Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 206010013486 Distractibility Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010050515 Hyposmia Diseases 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000883511 Lophophora williamsii Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241001421711 Mithras Species 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 241000272041 Naja Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010034703 Perseveration Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000022214 Post-traumatic amnestic disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 241000219287 Saponaria Species 0.000 description 1
- 240000003946 Saponaria officinalis Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000028979 Skull fracture Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 101710088929 Voltage-dependent L-type calcium channel subunit alpha-1S Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000002579 Wernicke Aphasia Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 235000019558 anosmia Nutrition 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940127248 antinauseant drug Drugs 0.000 description 1
- 230000004594 appetite change Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- GTKRFUAGOKINCA-UHFFFAOYSA-M chlorosilver;silver Chemical compound [Ag].[Ag]Cl GTKRFUAGOKINCA-UHFFFAOYSA-M 0.000 description 1
- 229910000424 chromium(II) oxide Inorganic materials 0.000 description 1
- AYTAKQFHWFYBMA-UHFFFAOYSA-N chromium(IV) oxide Inorganic materials O=[Cr]=O AYTAKQFHWFYBMA-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 231100000870 cognitive problem Toxicity 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000011961 computed axial tomography Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 238000012926 crystallographic analysis Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000991 decompressive effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000004720 dielectrophoresis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000002409 epiglottis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000010771 expressive aphasia Diseases 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- UQSQSQZYBQSBJZ-UHFFFAOYSA-M fluorosulfonate Chemical compound [O-]S(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-M 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 235000020021 gose Nutrition 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002218 isotachophoresis Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960002803 methaqualone Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108060006184 phycobiliprotein Proteins 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000000280 pituicyte Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000026759 receptive aphasia Diseases 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000010897 surface acoustic wave method Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Abstract
La divulgation concerne des méthodes qui aident à déterminer si un sujet présente un traumatisme crânien (TBI) par la détection de niveaux d'au moins un biomarqueur, tel que l'ubiquitine carboxy-terminale hydrolase L1 (UCH-L1), la protéine acide fibrillaire gliale (GFAP), ou une combinaison de ces dernières, dans des échantillons prélevés chez un sujet, tel qu'un sujet humain, le sujet ayant été soumis à un balayage CT de la tête ne démontrant pas de TBI.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163284421P | 2021-11-30 | 2021-11-30 | |
US17/538,572 | 2021-11-30 | ||
US63/284,421 | 2021-11-30 | ||
PCT/US2021/061215 WO2022119841A1 (fr) | 2020-12-01 | 2021-11-30 | Utilisation d'un ou plusieurs biomarqueurs pour déterminer un traumatisme crânien (tbi) chez un sujet soumis à un balayage de tomodensitométrie assistée par ordinateur de la tête à tbi négatif |
USPCT/US2021/061215 | 2021-11-30 | ||
US17/538,572 US20220170948A1 (en) | 2020-12-01 | 2021-11-30 | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi |
US202163294271P | 2021-12-28 | 2021-12-28 | |
US63/294,271 | 2021-12-28 | ||
PCT/US2022/080578 WO2023102384A1 (fr) | 2021-11-30 | 2022-11-29 | Utilisation d'un ou de plusieurs biomarqueurs pour déterminer un traumatisme crânien (tbi) chez un sujet ayant été soumis à un balayage de tomodensitométrie assistée par ordinateur de la tête ne démontrant par de tbi |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3239023A1 true CA3239023A1 (fr) | 2023-06-08 |
Family
ID=91130024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3239023A Pending CA3239023A1 (fr) | 2021-11-30 | 2022-11-29 | Utilisation d'un ou de plusieurs biomarqueurs pour determiner un traumatisme cranien (tbi) chez un sujet ayant ete soumis a un balayage de tomodensitometrie assistee par ordinateur de la tete ne demontrant par de tb |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2022401859A1 (fr) |
CA (1) | CA3239023A1 (fr) |
-
2022
- 2022-11-29 CA CA3239023A patent/CA3239023A1/fr active Pending
- 2022-11-29 AU AU2022401859A patent/AU2022401859A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022401859A1 (en) | 2024-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210389334A1 (en) | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1 | |
US20210088533A1 (en) | Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers | |
US20210102960A1 (en) | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers | |
AU2017339858B2 (en) | Improved methods of assessing GFAP status in patient samples | |
AU2018256845B2 (en) | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject | |
WO2018175942A1 (fr) | Méthodes d'aide au diagnostic et à la détermination de l'étendue d'une lésion cérébrale traumatique chez un sujet humain à l'aide du biomarqueur précoce hydrolase carboxy-terminale d'ubiquitine l1 | |
EP3602069A1 (fr) | Méthodes d'aide au diagnostic et à la détermination de l'étendue d'une lésion cérébrale traumatique chez un sujet humain à l'aide du biomarqueur précoce hydrolase carboxy-terminale d'ubiquitine l1 | |
US20240094226A1 (en) | Biomarkers for use in determining traumatic brain injury (tbi) | |
US20220170948A1 (en) | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi | |
US20230213536A1 (en) | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan | |
US20220381796A1 (en) | Methods of evaluating brain injury in a pediatric subject | |
US20240110928A1 (en) | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury | |
CA3239023A1 (fr) | Utilisation d'un ou de plusieurs biomarqueurs pour determiner un traumatisme cranien (tbi) chez un sujet ayant ete soumis a un balayage de tomodensitometrie assistee par ordinateur de la tete ne demontrant par de tb | |
WO2023102384A1 (fr) | Utilisation d'un ou de plusieurs biomarqueurs pour déterminer un traumatisme crânien (tbi) chez un sujet ayant été soumis à un balayage de tomodensitométrie assistée par ordinateur de la tête ne démontrant par de tbi | |
AU2021390474A1 (en) | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi | |
WO2023034777A1 (fr) | Méthodes et systèmes de diagnostic de lésion cérébrale |